[go: up one dir, main page]

PE20151005A1 - Composicion farmaceutica recubierta que contiene regorafenib - Google Patents

Composicion farmaceutica recubierta que contiene regorafenib

Info

Publication number
PE20151005A1
PE20151005A1 PE2015000289A PE2015000289A PE20151005A1 PE 20151005 A1 PE20151005 A1 PE 20151005A1 PE 2015000289 A PE2015000289 A PE 2015000289A PE 2015000289 A PE2015000289 A PE 2015000289A PE 20151005 A1 PE20151005 A1 PE 20151005A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition containing
coated pharmaceutical
containing regorafenib
regorafenib
Prior art date
Application number
PE2015000289A
Other languages
English (en)
Inventor
Susanne Skrabs
Adrian Funke
Mayk Kresse
Ulrich Oberdieck
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963450&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20151005(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of PE20151005A1 publication Critical patent/PE20151005A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893Tablet coating processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere a una composicion farmaceutica recubierta que contiene regorafenib, un hidrato, solvato, metabolito o sal farmaceuticamente aceptable del mismo, o un polimorfo del mismo y su procedimiento de preparacion y su uso para el tratamiento de desordenes, como el cancer
PE2015000289A 2012-09-06 2013-09-05 Composicion farmaceutica recubierta que contiene regorafenib PE20151005A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12183331 2012-09-06

Publications (1)

Publication Number Publication Date
PE20151005A1 true PE20151005A1 (es) 2015-06-27

Family

ID=46963450

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000289A PE20151005A1 (es) 2012-09-06 2013-09-05 Composicion farmaceutica recubierta que contiene regorafenib

Country Status (43)

Country Link
US (1) US20140065212A1 (es)
EP (2) EP2892507B1 (es)
JP (1) JP6445436B2 (es)
KR (1) KR102162036B1 (es)
CN (5) CN111249247A (es)
AP (1) AP2015008292A0 (es)
AR (1) AR092439A1 (es)
AU (1) AU2013312531B2 (es)
BR (1) BR112015004936B1 (es)
CA (1) CA2883767C (es)
CL (1) CL2015000544A1 (es)
CO (1) CO7310528A2 (es)
CR (1) CR20150114A (es)
CU (1) CU24244B1 (es)
CY (1) CY1118839T1 (es)
DK (1) DK2892507T3 (es)
EA (1) EA027685B1 (es)
ES (1) ES2623205T3 (es)
GT (1) GT201500053A (es)
HK (1) HK1214170A1 (es)
HR (1) HRP20170620T1 (es)
HU (1) HUE032758T2 (es)
IL (1) IL237350B (es)
IN (1) IN2015DN01673A (es)
JO (1) JO3479B1 (es)
LT (1) LT2892507T (es)
MA (1) MA37888B1 (es)
MX (1) MX359922B (es)
MY (1) MY176135A (es)
NZ (1) NZ705578A (es)
PE (1) PE20151005A1 (es)
PH (1) PH12015500460B1 (es)
PL (1) PL2892507T3 (es)
PT (1) PT2892507T (es)
RS (1) RS56019B1 (es)
SA (1) SA515360113B1 (es)
SG (1) SG11201501683WA (es)
SI (1) SI2892507T1 (es)
TW (1) TWI640329B (es)
UA (1) UA115994C2 (es)
UY (1) UY35006A (es)
WO (1) WO2014039677A1 (es)
ZA (1) ZA201501394B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
US20160220494A1 (en) * 2013-09-13 2016-08-04 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
CN104586808B (zh) * 2014-12-27 2017-08-18 北京元延医药科技股份有限公司 抗肿瘤药物组合物
CN105136956A (zh) * 2015-09-11 2015-12-09 江苏嘉逸医药有限公司 一种快速测定瑞戈非尼含量的方法
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN106880607A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种含有瑞戈非尼的口腔崩解片及其制备方法
CN106880615A (zh) * 2015-12-15 2017-06-23 北大方正集团有限公司 一种瑞戈非尼的口服固体制剂及其制备方法
CN105496975B (zh) * 2015-12-17 2019-01-04 河南润弘制药股份有限公司 一种瑞戈非尼片剂及其制备方法
CN106913527A (zh) * 2015-12-28 2017-07-04 江苏先声药业有限公司 一种瑞戈非尼速释微丸及其制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
IL270948B2 (en) * 2017-06-02 2025-07-01 Bayer Ag Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN112367995A (zh) * 2018-07-06 2021-02-12 安吉奥斯医药品有限公司 艾伏尼布形式和药物组合物
CN111053751A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 瑞戈非尼的缓释片剂及其制备方法
TWI799599B (zh) * 2019-06-06 2023-04-21 華納國際生物科技股份有限公司 醫藥或保健品自乳化固體分散組成物
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN113018274A (zh) * 2021-03-10 2021-06-25 药源生物科技(启东)有限公司 一种含羟丙甲纤维素的药物组合物及其制备方法
TR2023002707A2 (tr) * 2023-03-10 2024-09-23 Abdi̇ İbrahi̇m İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Regorafenib içeren bir farmasötik bileşim.
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100544717C (zh) * 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
CN1265793C (zh) * 2002-11-18 2006-07-26 杭州容立医药科技有限公司 左西替利嗪伪麻黄碱复方口服制剂及制备方法
KR101139557B1 (ko) 2003-07-23 2012-04-30 바이엘 파마슈티칼스 코포레이션 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
WO2007068381A1 (en) * 2005-12-15 2007-06-21 Bayer Healthcare Ag Diaryl ureas for treating inflammatory skin, eye and/or ear diseases
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
WO2008044111A1 (en) * 2006-10-13 2008-04-17 Pfizer Products Inc. Pharmaceutical formulation tablet
EP2101767A2 (en) * 2006-12-07 2009-09-23 Eli Lilly & Company An article comprising prasugrel
CA2703365A1 (en) * 2007-10-25 2009-04-30 Yuka Yamanouchi Nifedipine-containing press coated tablet and method of preparing the same
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
KR20200003219A (ko) * 2011-05-20 2020-01-08 아스트라제네카 유케이 리미티드 로수바스타틴 칼슘의 약학 조성물

Also Published As

Publication number Publication date
HUE032758T2 (en) 2017-10-30
CN116392598A (zh) 2023-07-07
IL237350A0 (en) 2015-04-30
CU20150020A7 (es) 2015-05-28
UA115994C2 (uk) 2018-01-25
MY176135A (en) 2020-07-24
MX359922B (es) 2018-10-16
SG11201501683WA (en) 2015-04-29
CA2883767A1 (en) 2014-03-13
MA37888A1 (fr) 2018-07-31
SI2892507T1 (sl) 2017-08-31
CU24244B1 (es) 2017-02-02
CY1118839T1 (el) 2018-01-10
LT2892507T (lt) 2017-06-12
MA37888B1 (fr) 2019-08-30
PL2892507T3 (pl) 2017-09-29
HRP20170620T1 (hr) 2017-06-30
AU2013312531B2 (en) 2017-10-19
EA201590520A1 (ru) 2015-10-30
TW201414510A (zh) 2014-04-16
IL237350B (en) 2020-11-30
HK1214170A1 (zh) 2016-07-22
PH12015500460A1 (en) 2015-04-20
AU2013312531A1 (en) 2015-03-12
KR102162036B1 (ko) 2020-10-07
CA2883767C (en) 2018-11-13
CN116392484A (zh) 2023-07-07
CL2015000544A1 (es) 2015-08-21
ZA201501394B (en) 2016-07-27
JP6445436B2 (ja) 2018-12-26
PH12015500460B1 (en) 2015-04-20
CR20150114A (es) 2015-05-11
BR112015004936B1 (pt) 2022-12-06
AP2015008292A0 (en) 2015-02-28
RS56019B1 (sr) 2017-09-29
CN116392485A (zh) 2023-07-07
EP2892507A1 (en) 2015-07-15
KR20150048872A (ko) 2015-05-07
US20140065212A1 (en) 2014-03-06
SA515360113B1 (ar) 2016-08-10
NZ705578A (en) 2017-10-27
CO7310528A2 (es) 2015-06-30
UY35006A (es) 2014-03-31
TWI640329B (zh) 2018-11-11
DK2892507T3 (en) 2017-05-01
EP2892507B1 (en) 2017-02-01
IN2015DN01673A (es) 2015-07-03
GT201500053A (es) 2015-10-12
EP3243508A1 (en) 2017-11-15
EA027685B1 (ru) 2017-08-31
AR092439A1 (es) 2015-04-22
PT2892507T (pt) 2017-05-02
CN104902878A (zh) 2015-09-09
CN111249247A (zh) 2020-06-09
MX2015002815A (es) 2015-05-15
JO3479B1 (ar) 2020-07-05
ES2623205T3 (es) 2017-07-10
WO2014039677A1 (en) 2014-03-13
BR112015004936A2 (pt) 2017-07-04
JP2015527395A (ja) 2015-09-17

Similar Documents

Publication Publication Date Title
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
MX2017002028A (es) Compuestos de pirrolopirimidina usados como agonista del receptor de tipo toll 7 (tlr7).
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
GB201118656D0 (en) New compounds
GB201209613D0 (en) New compounds
MX349004B (es) Nuevos compuestos.
BR112012027743A2 (pt) ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas
CR20130693A (es) Composición farmacéutica ortalmológica tópica que contiene regorafenib
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
EA201400444A1 (ru) Производные 2-оксопиперидинила
ECSP15026386A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора

Legal Events

Date Code Title Description
FG Grant, registration